Laparoscopic exploration is vital for detecting occult peritoneal metastasis (opm) in gastric cancer, significantly impacting patient outcomes. 22.2% of 653 patients showed opm+ initially, linked to worse survival (15.9 months vs not reached). Younger age, better ECOG status, primary gastric cancers, and specific CA72-4 levels were risk factors for opm+. Re-evaluating opm status post-treatment revealed […]
Category: Cytoreductive Surgery & Peritoneum
Surgical Limits in Cytoreduction for Pseudomyxoma Peritonei
Surgeons need to consider that extensive perigastric dissection during cytoreductive surgery can impair postoperative recovery without affecting oncologic outcomes. Patients undergoing severe perigastric dissection (GCL4) had delayed oral intake, longer reliance on parenteral nutrition, and extended hospital stays. Major morbidity, 30-day mortality, and long-term survival rates remained consistent across surgical levels. Tailoring recovery strategies may […]
Global Consensus on Managing Gastric Cancer Peritoneal Metastasis
Experts established clear guidelines for handling gastric cancer with peritoneal metastasis, crucial for improving patient outcomes. Consensus reached on 13 statements regarding diagnosis and treatment, with 75-100% agreement among 42 experts. A broader expert group, including medical oncologists, showed 12 of 13 statements agreed upon but struggled with systemic treatment consensus (52%). These guidelines aim […]
Robotic Surgery for Limited Peritoneal Metastatic Gastric Cancer Yields Positive Outcomes
Robotic cytoreduction and HIPEC can improve recovery in gastric cancer patients with limited peritoneal metastasis. 100% complete cytoreduction rate achieved with robotic technique. Median hospital stay was just 5 days, a notable reduction from traditional methods. Favorable outcomes include less blood loss (median 300 ml) and lower transfusion rates (22.2%). Major morbidity was 38.9% and […]
Neoadjuvant Chemo Fails to Improve Outcomes in Colorectal Metastases
Neoadjuvant chemotherapy before CRS/HIPEC for metachronous colorectal peritoneal metastases offers no survival benefit and increases complication risks. Patients receiving neoadjuvant chemotherapy had a complication rate of 25% versus 12.7% for those undergoing upfront surgery. Length of hospital stay increased to 12 days with neoadjuvant treatment compared to 10 days without. Surgeons should weigh these risks […]
High Variation in Expert Assessment of Peritoneal Malignancy
Surgeons face significant interobserver variation in evaluating peritoneal lesions despite their experience. Consensus on lesion scoring achieved in only 22.5% of cases among 50 expert surgeons (α = 0.174). Agreement on morphologic terms reached in 26.5% of images (α = 0.0902), with “tumor nodule” used 90.4% of the time (p < 0.001). Consensus prediction of […]
Gastric Cancer Peritoneal Metastasis Management Consensus Established
New guidelines for managing gastric cancer peritoneal metastasis (gcpm) offer surgeons a pathway to improve patient outcomes. Experts developed 13 consensus statements on diagnosis and treatment, with 75-100% agreement among a global panel. A broader survey yielded 12 out of 13 consensus among 63 experts, but only 52% agreed on systemic treatment best practices. This […]
PIPAC Treatment Linked to Longer Survival in Unresectable Malignancies
More treatments with pressurized intraperitoneal aerosol chemotherapy (PIPAC) lead to better survival outcomes for patients with unresectable peritoneal surface malignancies (PSMs). Patients receiving 3 or more PIPAC procedures showed significantly improved survival. Disease progression (56%) was the main reason for stopping treatment, signaling the need for ongoing evaluation of therapy effectiveness. Surgeons should consider the […]
Laparoscopic surgery yields similar outcomes for colorectal peritoneal metastases.
Survival rates are comparable: median overall survival is 37.3 months with laparoscopic versus 34.1 months with open surgery. Postoperative complications are similar in both groups, but hospital stays are shorter for laparoscopic patients. Patient selection is crucial; extraperitoneal metastasis significantly impacts survival outcomes. Consider laparoscopic cytoreductive surgery for suitable patients to enhance recovery without compromising […]
New Consensus Guidelines for Peritoneal Mesothelioma Care
A recent consensus on managing peritoneal mesothelioma reaffirms critical treatment strategies. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the standard for completely resectable cases. Strong agreement on using cisplatin-doxorubicin for HIPEC in routine care and performing a total parietal peritonectomy for all patients. Neoadjuvant chemotherapy recommended for patients with sarcomatoid or biphasic subtypes and […]